Literature DB >> 520501

Two novel prolactin release-inhibiting 8 alpha-amino-ergolines.

E Flückiger, U Briner, H R Bürki, P Marbach, H R Wagner, W Doepfner.   

Abstract

Prolactin secretion inhibition and changes in striatal dopamine metabolism in rats were compared after the administration of 8 alpha-amino-ergoline CH 29-717 and 2 derivates. CQ 32-084 was similar to but less potent than CH 29-717, while 32-085, the l-methyl derivative, showed delayed dopaminomimetic effects.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 520501     DOI： 10.1007/BF01953267

Source DB:  PubMed          Journal:  Experientia        ISSN： 0014-4754


  5 in total

1.  Prolactin secretion inhibition by a new 8alpha-amino-ergoline, CH 29-171.

Authors:  E Flückiger; U Briner; W Doepfner; E Kovacs; P Marbach; H R Wagner
Journal:  Experientia       Date:  1978-10-15

2.  Procedure for the simultaneous determination of dopamine, 3-methoxy-4-hydroxyphenylacetic acid, and 3,4-dihydroxyphenylacetic acid in brain.

Authors:  P F Spano; N H Neff
Journal:  Anal Biochem       Date:  1971-07       Impact factor: 3.365

3.  Dopamine inhibits adenylate cyclase in human prolactin-secreting pituitary adenomas.

Authors:  P De Camilli; D Macconi; A Spada
Journal:  Nature       Date:  1979-03-15       Impact factor: 49.962

4.  The interaction of the serotonergic and dopaminergic systems on prolactin secretion in the rat. The mechanism of action of the "specific" serotonin receptor antagonist, methysergide.

Authors:  S W Lamberts; R M MacLeod
Journal:  Endocrinology       Date:  1978-07       Impact factor: 4.736

5.  Neurochemical and neuropharmacological investigations with four ergot derivatives: bromocriptine, dihydroergotoxine, CF 25-397 and CM 29-712.

Authors:  J M Vigouret; H R Bürki; A L Jaton; P E Züger; D M Loew
Journal:  Pharmacology       Date:  1978       Impact factor: 2.547
  5 in total
  8 in total

1.  [3H]205-501, a non-catechol dopaminergic agonist, labels selectively and with high affinity dopamine D2 receptors.

Authors:  A Closse; W Frick; R Markstein; R Maurer; R Nordmann
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

2.  Therapeutic experience with the new dopamine agonist CU 32-085 in advanced Parkinson's disease.

Authors:  H Biesemeyer; H P Ludin; E Ringwald
Journal:  J Neurol       Date:  1983       Impact factor: 4.849

3.  Mesulergine and bromocriptine in long-term treatment of advanced parkinsonism.

Authors:  H Baas; E Schneider; P A Fischer; G Japp
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

4.  Pharmacodynamic profile of CQP 201-403, a novel 8 alpha-amino-ergoline.

Authors:  E Flückiger; U Briner; B Clark; A Closse; A Enz; P Gull; A Hofmann; R Markstein; L Tolcsvai; H R Wagner
Journal:  Experientia       Date:  1988-05-15

5.  On the mode of action of six putative dopamine receptor agonists on suppression of exploratory behaviour in rats.

Authors:  L Ståhle; U Ungerstedt
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

6.  Mesulergine in early Parkinson's disease: a double blind controlled trial.

Authors:  E Dupont; B Mikkelsen; J Jakobsen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-04       Impact factor: 10.154

7.  Three-year observation of mesulergine (CU 32-085) in advanced and newly treated parkinsonism.

Authors:  E Schneider; H Baas; P A Fischer; G Japp
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

8.  Dopaminergic properties of mesulergine (CU 32-085) and its metabolites.

Authors:  A Enz; P Donatsch; R Nordmann
Journal:  J Neural Transm       Date:  1984       Impact factor: 3.575
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.